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A B S T R A C T
Background: The development of prostate tumors has been linked to co-morbid diabetes mellitus (DM) in
several studies, potentially through the stimulation of insulin-like growth factor receptor (IGFR). This
study evaluates the effect of anti-diabetic medication use on the development of high grade tumors and
time to tumor progression compared to non-diabetics.
Methods: This retrospective, nested case control study identiﬁed patients with prostate cancer (PCa)
from the Kentucky Medicaid Database. Cases were diagnosed with PCa and DM and using at least one of
the following antidiabetic medications; sulfonylureas, insulin, metformin or TZDs. Cases were further
stratiﬁed on their insulin exposure resulting from therapy. Controls were those with PCa without DM or
any anti-diabetic medications.
Results: The use of metformin or TZDs trended toward decreased odds of high-grade tumors and
decreased risk of progression, while sulfonylureas and high-dose insulin tended toward an increased
odds of high-grade tumors and increase the risk of progression compared to non-diabetics.
Conclusions: Future studies should be conducted to further evaluate the effects of anti-diabetic
medications on tumor grade and time to prostate cancer progression.
 2012 Elsevier Ltd. 
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Prostate cancer (PCa) is the most common cancer of men in the
United States, affecting nearly 2.4 million men in 2008 [1].
Currently 11.8% of the adult male population (13 million men) are
estimated to have a diagnosis of diabetes, 90–95% of which is
considered to be type II (T2DM) [2]. Unlike type I diabetes, which is
deﬁned as a pathologic lack of insulin, T2DM is primarily due to
increased insulin resistance, necessitating increasing doses of
insulin. While the most prominent long-term effects of diabetes
are cardiovascular complications, recent studies have demonstrat-
ed a relationship between diabetes, insulin exposure and cancer
risk [3–9]. Namely, diabetes has been found to independently
correlate with tumor grade, lower prostate speciﬁc antigen (PSA)
levels, and an overall decreased risk of prostate cancer [3,6,10–17].
While diabetes has been shown to decrease cancer risk, elevated
circulating insulin has been associated with increased Gleason
scores, tumor growth, and mortality [7,18,19]. Furthermore, the* Corresponding author at: Oncology Pharmacy Specialist, Jewish Hospital/St.
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Open access under CC BY license.duration of diabetes diagnosis also appears to affect this
relationship, with those with long-standing T2DM (and therefore
lower circulating insulin) having a lower risk than newly
diagnosed patients [19,20]. One prominent hypothesis to explain
this causal relationship focuses on the role of insulin exposure and
the insulin-like growth factor receptor (IGF-1R) as a primary non-
hormonal driver of tumorgenesis [4,5,7].
IGF-1R is a type 2 tyrosine kinase receptor, expressed on both
normal tissue as well as numerous cancer cell lines, including
prostate cancer. When stimulated by insulin or IGF, IGF-1R
activates known mitogenic and anti-apoptotic pathways such as
PI3K/AKT and RAS/RAF/MAPK causing subsequent aberrant cell
growth [18,21–23]. Thus, insulin and IGF-1R signaling serves as an
important driver of prostate cancer growth and invasion.
Increasing levels of IGFR-1 expression is associated with
increased levels of prostate speciﬁc antigen (PSA) and higher
Gleason score values, both of which indicate increased aggres-
siveness and poorer prognosis [18,24,25]. Furthermore, IGFR-1
antagonism has been shown to be associated with decreased
androgen-dependent and independent growth [26].
Antidiabetic pharmacotherapy can inﬂuence the exposure to
exogenous and endogenous insulin, potentially impacting tumor
development and growth [27]. Epidemiologic studies have
demonstrated a greater risk of cancer for those using insulin
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secretagogue agents (i.e. sulfonylureas) have been associated with
an increased risk of cancer-related mortality, across all tumor
types, while non-insulin stimulating agents like metformin and,
thiazolidinediones (TZDs) appear to have little effect on tumor-
related outcomes [29–31]. Speciﬁcally looking at prostate cancer,
the effect of oral agents remains unclear; while some studies have
reported decreased risk of tumor development for all agents,
others cite and increase risk for insulin-stimulating agents over
metformin [5,32,33]. From this information it is clear that the
interaction of these agents with tumor development and growth is
unclear and more investigation is needed to guide prudent
medication selection in diabetic men at-risk for prostate tumors.
In addition to these observed relationships, other factors may
also impact the complex interactions of prostate cancer and
diabetes. Recent research has suggested that obesity, hyperten-
sion, hypercholesterolemia, either individually or as metabolic
syndrome may also play a role in the development of higher-grade
cancer (Gleason score 7) as well as increased progression,
potentially through their effects on physiologic glucose and insulin
[8,34]. Concurrent medication use, such as bisphosphonates,
corticosteroids, and androgen-deprivation therapy (ADT) has all
been shown to affect tumor progression as well as the develop-
ment hyperglycemia, diabetes, and metabolic syndrome [35–37].
Social factors such as rurality/access to care may also inﬂuence the
development and subsequent treatment of prostate cancer and
should be accounted for [38–40].
The relationship between insulin, diabetes and prostate cancer
is complex with multiple modifying factors. An improved
characterization of this association on the development and
progression of prostate tumors could potentially impact thousands
of patients. Based upon previous epidemiologic, animal and in vitro
studies we hypothesize that increased insulin exposure will
increase the initial tumor invasiveness as measured by Gleason
score and shorten the time to disease progression.
2. Methods
2.1. Study design
This retrospective nested case-control study used the Kentucky
Medicaid (KM) population, with additional data and validation
provided by the Kentucky Cancer Registry (KCR). The KM database
contains billing information, identiﬁed through International
Disease Classiﬁcation 9th revision (ICD-9) and Current Procedural
Terminology (CPT) codes on healthcare utilization including
procedures, medication use and diagnoses of low-income patients.
The KCR is a mandatory state cancer reporting system that is part
of the National Cancer Institute’s Surveillance Epidemiology End
Results (SEER) program [41]. The protocol was approved by the IRB
at the University of Kentucky, the Kentucky Cabinet for Health and
Family Services and the Kentucky Cancer Registry.
2.2. Study population
All male patients >18 years with a diagnosis of prostate cancer
between July 1, 2000 and December 31, 2005 were identiﬁed. In
the event that diagnosis dates differed between the KM and KCR
databases, information was used from the KCR database due to the
independent validation of this dataset in accordance with SEER
program. Patients were followed until the last date of contact or
August 31, 2009, whichever came ﬁrst. Patients must have had
Medicaid enrollment for >11 months to allow for medication use
analysis.
Prostate cancer diagnosis was determined through the ICD-9
diagnosis codes for primary prostate gland cancer (ICD9 185.x) andprimary prostate utricle cancer (ICD9 189.3). Patients with benign
lesions or carcinoma in situ were excluded. Patients must have
reported at least two cancer-related visits to a healthcare provider
within 1 year.
Cases were patients with T2DM at risk for increased insulin
exposure due to injectable and oral antidiabetic agents. Cases were
further stratiﬁed into cases with (a) T2DM and elevated serum
insulin exposure and (b) T2DM without elevated serum insulin
exposure. T2DM were deﬁned in accordance with the Healthcare
Effectiveness Data and Information Set (HEDIS) deﬁnition; (a) two
T2DM related healthcare visits (ICD 250.x2 or 250.x0) and (b)
prescription for an antidiabetic medication ﬁlled within 1 year
after the visit. The presence of type I diabetes was not eligible for
study inclusion due to the inefﬁcacy of oral agents in these
patients.
Cases subclassiﬁcation was based on insulin exposure due to
antidiabetic medication use. The deﬁnition of physiologic doses of
exogenous insulin was based on standard replacement therapy
guidelines used in type 1 DM:
 Elevated insulin exposure: Patients using agents known to cause
increase in endogenous insulin production, or utilizing supra-
physiologic doses of exogenous insulin. Includes sulfonylureas,
insulin at doses >0.8 units/kg/day (high-dose; utilized an
average weight of 85 kg determined from internal data on the
weight of prostate cancer patients in Kentucky) or combination
therapy with either of these agents for >2/3 the entire study
period.
 Physiologic insulin exposure: Patients using agents with no known
effect on endogenous insulin production or utilizing physiologic
doses of exogenous insulin. Includes metformin, TZDs, insulin at
doses 0.8 units/kg/day, or combination therapy for >2/3 of the
study period, without high-dose insulin or sulfonylureas use.
Those with unclear combination therapy for >2/3 the study
period, one-time medication use or poor diabetes medication
compliance were classiﬁed as indeterminate insulin exposure.
Cases were age-matched to controls in randomized blocks of 2,
allowing for up to 2 controls for every case.
Controls were chosen to compare not only the effect of
extracellular insulin on progression of disease, but also the effect
of T2DM on progression of disease. Controls were patients without
the risk of elevated insulin exposure; they lacked a diagnosis of
types I or II diabetes, or the receipt of an antidiabetic medication at
any time during the study observation.
Patients with an ICD-9 diagnosis of diabetes, but no prescrip-
tions for diabetes treatment were excluded. Patients using
repaglinde, nateglindine, a-glucosidase inhibitors were not
included due to variable insulin exposure. Agents such as
exenatide, pramlintide or sitagliptin were not present in the
Medicaid population during the study period.
Additional data collected include: medication use (including
steroid and bisphosphonate use), geography, comorbidity index,
tumor grade, tumor stage, metastatic sites, surgical information,
time with diagnosis of diabetes within the study period and
compliance. Medication use was deﬁned as use prior to cancer
diagnosis (for primary analysis) or recurrence (for secondary
analysis); steroid use was limited to those with use for 30 days.
Geography was determined through the use of the United States
Department of Agriculture (USDA) Rural-Urban continuum codes
[42]. The co-morbidity index was calculated using the Charlson
score. The Charlson score is a weighted composite score that
evaluates the presence of 22 conditions, including cancer [43]. The
Charlson score was calculated prior to the diagnosis of cancer to
reduce falsely elevated comorbid disease. Medication Possession
Ratio (MPR) was used to evaluate medication compliance of
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calculated as the sum of the days supply medication over a time
period divided by the time period of evaluation [44]. An MPR of
<80% was used to determine poor diabetes medication compliance
and led to study exclusion.
2.3. Determination of endpoints
Gleason score information is available as part of the KCR
database from pathology reports at the time of diagnosis. Patients
with a Gleason score 7 were considered to have high grade, more
aggressive tumors.
Time to progression was a composite endpoint classiﬁed
through ICD-9 and CPT codes in the KM database. Patients
experiencing any of the following events 60 days after the
diagnosis of prostate cancer were considered to have progressed:
 Recorded elevation of PSA ICD-9 code (790.93) at any point after
the index date of PSA normalization.
 Initiation of chemotherapy (CPT codes 96401–96549) or the
presence of chemotherapy within the KM prescription database
(low dose oral methotrexate was excluded).
 Recorded secondary cancer diagnosis, not diagnosed as meta-
static. This was based on ICD9 codes and sites of metastatic
spread including bone/spine, regional lymph nodes, bladder,
kidney, liver, lung, colon/rectum and other pelvic/genital
structures [45].
2.4. Statistical analysis
Demographic variables were evaluated using descriptive
statistics. Simple comparisons of continuous variables between
the study groups used ANOVA testing for normally distributed data
and Kruskal–Wallis testing for non-parametric variables. Categor-
ical variables were evaluated using chi-square testing of indepen-
dence; however, when low cell counts were found, Fisher’s exact
testing was utilized. All tests were 2 sided with a = 0.05 where
appropriate.
The primary endpoint was the presence of high Gleason score at
diagnosis. An odds ratio of the presence of high Gleason score
between cases and controls was evaluated through bivariate and
multivariate conditional logistic regression to control for con-
founders. Confounders included in the analysis were geography,
comorbidity measure and steroid use prior to diagnosis regardless
of the results of the bivariate model. The secondary endpoint was
the time to progression as deﬁned above. Kaplan–Meier survival
curves and log-rank testing evaluated the differences in time to
progression between insulin exposure groups. Cox proportional
hazard regression was used to evaluate the overall hazard ratios,
accounting for confounders of geography, comorbidity, stage/
metastatic spread, and steroid and bisphosphonate use prior to
recurrence. Statistical analysis was performed using STATA v.10
(StataCorp LP, College Station, TX, USA).
3. Results
Out of 1272 patients initially identiﬁed, 722 patients were
eligible for inclusion. A diagram of exclusion is provided in Fig. 1. Of
these patients, 50 were found to have physiologic insulin exposure,
103 had elevated insulin exposure, and 16 had indeterminate
exposure. The remaining 569 patients had no evidence of diabetes.
From this, 338 were randomly age-matched and selected as
controls. Those with indeterminate exposure were excluded from
the ﬁnal analysis due to low numbers, leading to a total of 491
patients evaluated. Demographic information is listed in Table 1.Within the 491 patients, 236 were found to have evaluable
pathologic information, including Gleason score. One-hundred
forty-nine (59.36%) were found to have a Gleason score <7, while
102 (40.64%) were diagnosed with high-grade disease. A break-
down of this by insulin exposure group is in Fig. 2. Overall diabetic
patients, regardless of insulin exposure, presented with lower
Gleason scores, although this was not statistically signiﬁcant.
Compared to those without diabetes, patients with elevated
exposure had a 5% lower odds (95% CI: 0.47–1.91; p = 0.887) of
developing high-grade disease, while those with physiologic
exposure had a 45% lower odds (95% CI: 0.21–1.46; p = 0.233).
When adjusted for geography, co-morbidity, and corticosteroid
use prior to prostate cancer diagnosis, elevated insulin exposure
appeared to slightly increase the odds of presenting with high-
grade disease (OR = 1.04 (0.44–2.44); p = 0.685), while physiologic
insulin exposure decreased the odds (OR = 0.62 (0.22–1.70);
p = 0.929) compared to controls (Table 2), although neither of
these ﬁndings were statistically signiﬁcant.
Evaluating the secondary endpoint (Fig. 3), 122 patients were
found to have recurrence. Median time to recurrence was 31.4
(0.03–98.1) months for those with physiologic exposure compared
to 27.6 (1.38–92.7) months for those with elevated insulin
exposure and 26.6 (0.92–96.2) for those without diabetes
(p = 0.8623). Adjusting for potential confounders, there was no
signiﬁcant effect of insulin exposure on the time to tumor
progression, although it appeared that elevated insulin exposure
may increase the risk of progression, while physiologic exposure
decreases the risk of progression compared to non-diabetics (Table
3). Only the use of steroids prior to recurrence was found to have a
statistically signiﬁcant impact on the time to tumor progression. A
68% decrease (p = 0.019) in the risk of progression over the ﬁve
years studied was found in patients that used corticosteroids when
controlling for other factors.
4. Discussion
This study found that management of diabetes with medica-
tions which create supra-physiologic serum insulin exposure does
not lead to more aggressive prostate cancers at diagnosis or shorter
time to progression, although due to limited power needs to be
investigated further. Previous analyses have demonstrated a link
between diabetes and developing cancer, an effect which is
potentially modiﬁed by the choice of antidiabetic treatment [29–
33]. In vitro studies clearly demonstrate that extra-cellular insulin
can stimulate IGFR-1 receptors in prostate cancer cell lines,
activating mitogenic and angiogenesis pathways. These ﬁndings
suggest that this is not a disease–disease interaction, but rather a
disease treatment–disease interaction. While several others have
evaluated the association of diabetes and cancer, none have
focused on the impact of serum insulin exposure from disease
management.
Recent data released by the Health Professionals Study suggest
that tumors with Gleason score <7 are associated with higher
levels of insulin-like growth factor and binding protein (IGF-1 and
IGFBP-3) [46]. The data in the Health Professionals Study suggests
that increasing insulin levels may actually lead to lower-grade
tumors in patients with high serum insulin who develop cancer.
This proposed mechanism is counter to what has been seen in
previous in vitro, in vivo, and epidemiologic analyses, and those
used in the development of the hypothesis evaluated in this study
[13,47,48]. In further evaluating this, alternate hypotheses for
increased high-grade tumors in patients with elevated insulin
exposure should be further investigated.
One potential rationale for the differences in effect seen
between this study, the Health Professionals Study and previous
investigation may be from the effect of DM on testosterone.
40.48%
30.43%
43.02%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
Elevated Insulin Exposure Physiologic Insulin 
Exposure
No Diabetes
Pe
rc
en
t o
f p
at
ie
nt
s 
pe
r g
ro
up
 w
ith
 
hi
gh
/lo
w
 G
le
as
on
 s
co
re
s Gleason score ≥7
n=17 
n=7
n=74
Fig. 2. Gleason score based on insulin exposure.
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Fig. 3. Kaplan–Meier analysis of time to progression by insulin exposure.
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Table 1
Patient demographic information.
Elevated
insulin
exposure
Physiologic
insulin
exposure
No evidence
of DM
Total p-Value
N 103 (20.98%) 50 (10.18%) 338 (68.84%) 491
Age (years) (mean, SD) 70.8 (9.78) 71.2 (9.32) 70.6 (10.18) 70.7 (9.99) 0.9250
Geography 0.651
Urban 32 (31.07%) 10 (20.00%) 96 (28.40%) 138 (28.11%)
Suburban 16 (15.53%) 11 (22.00%) 61 (18.05%) 88 (17.92%)
Rural 55 (53.40%) 29 (58.00%) 181 (53.55%) 265 (53.97%)
Stage* n = 62 n = 30 n = 202 n = 294 0.281
Localized 46 (74.19%) 26 (86.67%) 142 (70.30%) 214 (72.79%)
Regional 4 (6.45%) 0 (0%) 11 (5.45%) 15 (5.10%)
Distant metastases 7 (11.29%) 2 (6.67%) 39 (19.31%) 48(16.33%)
Unknown/unstageable 5 (8.06%) 2 (6.67%) 10 (4.95%) 17 (5.78%)
Presence of metastases at diagnosis 0.159
No 96 (93.20%) 48 (96.00%) 299 (88.46%) 443 (90.22%)
Yes 7 (6.80%) 2 (4.00%) 39 (11.54%) 48 (9.78%)
Metastatic sites 0.119
No metastatic sites 96 (93.20%) 48 (96.00%) 299 (88.46%) 443 (90.22%)
Bone/spine 1 (0.97%) 2 (4.00%) 15 (4.44%) 18 (3.67%)
Other sites 6 (5.83%) 0 (0%) 24 (7.10%) 30 (6.11%)
Comorbidity information
Charlson scores (median, range)* 2 (1–7) 2 (1–5) 1 (1–12) 2 (1–12) 0.0351
n = 86 n = 40 n = 173 n = 299
Medication use
Chemotherapy use 0.088
No 90 (87.38%) 49 (98.00%) 308 (91.12%) 447 (91.04%)
Yes 13 (12.62%) 1 (2.00%) 30 (8.88%) 44 (8.96%)
Antiandrogen/GNRH agonist use 0.869
No 82 (79.61%) 38 (76.00%) 266 (78.70%) 386 (78.62%)
Yes 21 (20.39%) 12 (24.00%) 72 (21.30%) 105 (21.38%)
Bisphosphonate use 0.706
No 96 (93.20%) 48 (96.00%) 311 (92.01%) 455 (92.67%)
Yes 7 (6.80%) 2 (4.00%) 27 (7.99%) 36 (7.33%)
Corticosteroid usea 0.118
No 82 (79.61%) 45 (90.00%) 262 (77.51%) 389 (79.23%)
Before diagnosis 5 (4.85%) 1 (2.00%) 8 (2.37%) 14 (2.85%) 0.346
Spanning diagnosis 12 (11.65%) 4 (8.00%) 43 (12.72%) 59 (12.02%) 0.722
After diagnosis 4 (3.88%) 0 (0.00%) 25 (7.40%) 29 (5.91%) 0.068
Diabetes information
Time diagnosed with DM (years) (median, range) 4.2 (0.16–9.61) 3.9 (0.16–9.59) 0 (0) 4.1 (0.16–9.61) 0.515
Time from diagnosis of DM to diagnosis of PCa
(years) (mean, SD)
1.8 (1.89) 1.8 (2.01) 0 (0) 1.8 (1.93) 0.851
Antidiabetic medication use
Sulfonylurea use
No sulfonylurea use 10 (9.71%) 38 (76.00%) 338 (100%) 386 (78.62%)
Sulfonlyurea + other DM 69 (66.99%) 12 (24.00%) 0 (0%) 81 (16.50%) <0.001
Exclusive sulfonylurea 24 (23.30%) 0 (0%) 0 (0%) 24 (4.89%) <0.001
Thiazolendione use (TZD)
No TZD use 69 (66.99%) 26 (52.00%) 338 (100%) 433 (88.19%)
TZD + other DM med 34 (33.01%) 18 (36.00%) 0 (0%) 52 (10.59%) <0.001
Exclusive TZD 0 (0%) 6 (12.00%) 0 (0%) 6(1.22%) <0.001
Metformin use
No metformin use 48 (46.60%) 19 (38.00%) 338 (100%) 405 (82.48%)
Metformin + other DM 55 (53.40%) 17 (34.00%) 0 (0%) 72 (14.66%) <0.001
Exclusive metformin 0 (0%) 14 (28.00%) 0 (0%) 14 (2.85%) <0.001
Insulin use
No insulin use 60 (58.25%) 31 (62.00%) 338 (100%) 429 (87.37%)
Insulin + other DM 37 (35.92%) 14 (28.00%) 0 (0%) 51 (11.88%) <0.001
Exclusive insulin 6 (5.83%) 5 (10.00%) 0 (0%) 11 (2.24%) <0.001
Average medication possession ratio (MPR) of
diabetic meds (median, range)
1.00 (0.80–4.72) 0.99 (0.82–3.53) 0 (0) 1.00 (0.80–4.72) 0.797
Use of antidiabetic medications after PCa dx
(as percent of total DMgrp)
14 (13.59%) 11 (22.00%) 0 (0%) 25 (5.09%)
* Not available for all patients; number evaluated listed.
a Differences between the steroid group overall listed ﬁrst; differences listed with each point of steroid use (before, during, after) are listed at the point of use–these were
determined from dichotomous values (e.g. used/did not use steroid before diagnosis)
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known stimulatory agent of prostate cancer growth. Further,
testosterone has been associated with higher-grade tumors [49–
51], a ﬁnding that supports what was seen in the studies by Hong
and DeNuzio [13,34]. As demonstrated there are conﬂicting
reports, and potentially conﬂicting underlying biochemical mech-
anisms regarding the effect of diabetes on prostate tumor grade.This highlights the importance of further study in this area with
clear measurement of the effect of serum insulin, insulin/IGFR-1
receptors and testosterone on tumor grade.
Another potential factor leading to the disparities seen within
studies may be due to the effect of obesity and other components
of metabolic syndrome on tumor development. Increased BMI,
weight, and hypercholesterolemia have been associated with
Table 3
Multivariate analysis of hazard of prostate cancer progression (n = 168).
Hazard ratio 95%
Conﬁdence
interval
p-Value
Rurality
Urban Reference
Suburban 0.82 (0.31–2.15) 0.684
Rural 0.68 (0.30–1.53) 0.351
Charlson score 0.85 (0.62–1.16) 0.313
Stage
Localized Reference
Regional 0.96 (0.28–3.30) 0.945
Distant Metastases 0.96 (0.36–2.53) 0.926
Unknown/unstageable 1.83 (0.42–8.01) 0.421
Corticosteroid use (prior to recurrence)
No Reference
Yes 0.32 (0.13–0.83) 0.019
Bisphosphonate use (prior to recurrence)
No Reference
Yes 2.01 (0.64–6.35) 0.232
Antiandrogen/GNRH agonist use (prior to recurrence)
No Reference
Yes 0.91 (0.43–1.93) 0.814
Diabetes group
No Diabetes Reference
Elevated insulin exposure 1.18 (0.57–2.44) 0.649
Physiologic insulin exposure 0.62 (0.22–1.73) 0.363
Physiologic compared to
elevated
0.58 (0.22–1.53) 0.272
Table 2
Multivariate analysis of odds of developing high Gleason score based on insulin
exposure (n = 133).
Odds Ratio 95%
Conﬁdence
Interval
p-value
Rurality
Urban Reference
Suburban 0.50 (0.17–1.52) 0.222
Rural 0.74 (0.30–1.80) 0.500
Charlson score 1.07 (0.79–1.44) 0.670
Corticosteroid use (before dx)
No Reference
Yes 1.47 (0.23–9.46) 0.685
Diabetes group
No diabetes Reference
Elevated insulin exposure 1.04 (0.44–2.44) 0.929
Physiologic insulin exposure 0.61 (0.22–1.70) 0.350
Physiologic compared to
elevated
0.61 (0.23–1.62) 0.320
A. Hitron et al. / Cancer Epidemiology 36 (2012) e243–e250e248increased risk of high-grade tumor development, independent of
the effect of DM or insulin exposure [6,34,52,53]. It is thought
that alterations in lipid and androgen metabolism may lead to
these effects. Due to the limitations of the KM database, BMI and
weight information was not available. The interaction between
DM, other factors in metabolic syndrome, serum insulin and
tumor growth is complex and should be continue to be evaluated
in the future.
Although epidemiologic evidence exists suggesting that the use
of antidiabetic therapy may alter the development of prostate
tumors, again, no evidence exists that these agents alter tumor
grade. In this evaluation, the use of insulin stimulating agents was
associated with a slight increase in high grade tumors while non-
stimulating agents were associated with a lower grade tumor
compared to those without diabetes. While this is not statistically
signiﬁcant, this does provide evidence that perhaps the increase in
serum insulin seen may lead to increased mitogenic effects. This
study was only able to access data from the Kentucky Medicaiddatabase over a 5-year period, leading to low study power. In
addition to the small sample size gained from this database, the
Kentucky Medicaid population is limited to low-income patients.
Although efforts were taken to ensure that the demographics of
this population was representative of the larger American
population, Medicaid patients inherently have different access
to care that may have limited the ability to determine statistically
signiﬁcant differences. Evaluation in a larger nation-wide data-
base, such as the Veteran’s Administration or private insurance
databases may provide further clarity on the effect of diabetic
medication use on the development of high-grade prostate tumors.
Similarly, the difference in the time to tumor progression based
on the use of antidiabetic medications has not been previously
evaluated in the literature. Overall, this study found a potentially
lower risk of tumor progression in those using TZDs, metformin or
low-dose insulin compared to non-diabetics and a higher risk of
progression in those using sulfonylureas or high-dose insulin
compared to non-diabetics. Although this was not statistically
signiﬁcant, this observed decrease in tumor progression may not be
due to the effects of these agents on insulin production and serum
mobilization, but rather from non-insulin dependent anti-tumor
effects of metformin and TZDs. Metformin has been shown inhibit in
vitro growth of prostate cell lines through AMPK activation and
mTOR inhibition [54]. Thiazolidinediones have also been shown to
have independent anti-tumor activity in vitro. This effect is thought
to be primarily through the activation of PPAR-g, although PPAR-g
independent mechanisms have also been suggested [55]. Although
sulfonylureas have not yet been shown to have antitumor effects, it
is thought that the effects on increased tumor risk and mortality seen
with sulfonylureas may be a statistical abnormality due to the
comparison to those with known anti-tumor activity [56]. In this
study metformin and TZDs were associated with a potentially
decreased time to progression, while sulfonylureas had a slight
increase in progression. Since the anti-tumor effects were unable to
be accounted for it is difﬁcult to ascertain if the effects seen were a
result of the effect on insulin, or a modiﬁcation of alternate
tumorgenic cellular pathways by diabetic medications. Further
evaluation in larger datasets should be continued to elucidate the
effects of medication-induced insulin stimulation on the develop-
ment and progression of prostate tumors.
Comparing the impact of patients both case groups vs. controls
with T2DM, an overall decrease in tumor progression in patients
with elevated and physiologic insulin exposure compared to those
without DM. Similar to the results of the primary evaluation, this
was not statistically signiﬁcant, but leads to interesting observa-
tions on the effect of DM on tumor progression. In addition to
potential anti-tumor effects of diabetic medications, the decrease
in progression risk in those with elevated exposure may indicated a
protective effect of physiologic changes in diabetic patients.
Vascular changes are common in diabetics, often leading to
numerous complications on end-organs. Post hoc analysis
demonstrated that overall case patients in both groups had a
lower incidence of metastatic disease than non-diabetics, indicat-
ing that despite potentially higher grade at diagnosis, diabetics
may have less metastatic spread due to poor vascularization. This
hypothesis could not be evaluated in this analysis, but should
continue to be investigated in future studies.
5. Conclusion
The use of antidiabetic medications that cause high insulin
exposure did not increase the grade of prostate tumor upon
diagnosis or decrease the time to tumor progression in this
analysis. Although the results were inconclusive this data provides
needed insight into the interactions between diabetes treatments
and the development and progression of prostate tumors. While
A. Hitron et al. / Cancer Epidemiology 36 (2012) e243–e250 e249this study was underpowered to provide any conclusive results,
the hypothesis remains credible and should continue to be
investigated through larger database analyses, as well as potential
prospective studies. As seen, there is a multitude of factors that
interplay within the proposed mechanism to lead to tumor
development and progression. Future analysis should consider an
evaluation of serum insulin, weight, BMI, lipids (cholesterol, HDL,
LDL, TG), testosterone, and IGFR-1 expression on pathologic
samples, along with robust medical histories (including complete
antidiabetic and lipid-lowering agents, bisphosphonate use,
hormone therapy, and steroid medications histories) in order to
fully evaluate the effect of medications on prostate tumors.
Through a better characterization of these interactions, future
treatment of patients with diabetes and prostate cancer may be
optimized and overall health outcomes improved.
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